Travere Therapeutics Reports First Quarter 2024 Financial Results

FDA grants Priority Review for sNDA to convert FILSPARI ® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S. ; PDUFA target action date of September 5, 2024 Received 511 new patient start forms (PSFs) for FILSPARI   in Q1 2024; Total of 1,963 PSFs received

View Full Press Release